

A Randomized, Double-Blind, Clinical Study to Evaluate the Safety and Efficacy of SpeedGel Rx® in the Symptomatic Treatment of Osteoarthritis in the Interphalangeal Joints

Background

This study evaluated the efficacy of SpeedGel Rx® for the treatment of Osteoarthritis of the Interphalangeal joints. In a two-week, randomized, double-blind, placebo-controlled, parallel-group trial, SpeedGel Rx® was administered at a dose of four times daily on the treatment hand. Pain was assessed using a 10-point visual analog scale. The reliability of the scale has been demonstrated in multiple studies.

Findings:

1. By day two pain was lower in the treatment group than the control group.
2. By day five pain was over 10% lower in the treatment group.
3. Overall a 60% reduction in pain was found between the treatment group from baseline.
4. No subject in the treatment group reported a side effect.
5. A majority of subjects in the treatment group were taking some type of blood thinner.

Figure 1. Time Plot of Pain Reduction by Treatment Method

